Can-C eye drops have been attracting attention as a safe, simple and highly effective way to treat senile cataracts and other eye ageing conditions – without surgery.
Pioneered by respected bio-physicist Dr Mark Babizhayev and a team of Russian researchers in the early 1990s, Can-C eye drops contain a potent anti-ageing and anti-oxidant known as N-acetylcarnosine, or NAC for short.
NAC combats the build up of free radicals in our body – the molecules which cause tissue damage and accelerate the ageing process - and are a leading cause of cataracts.
NAC is a naturally occurring compound, related to the nutrient di-peptide carnosine (a di-peptide refers to two amino-acids, or protein fragments, which are linked together). Carsonine
effectively ‘mops up’ and repairs the damage caused by free radicals in the eye.
Getting carsonine into the body presents a challenge, however. The natural enzymes in the eye react with carsonine, reducing its potency to tackle free radicals. Can-C’s NAC formulation is highly resistant to this reaction - while its slow release formulation gradually breaks down in the eye to deliver carsonine effectively.
The NAC formulation also tackles the impact of UV radiation – another important factor in eye health and degeneration.
Age-related or ‘Senile’ cataract is a progressive eye condition affecting the lens of the eye. As we get older, the lens may become hard, opaque and cloudy. This process affects the amount of light which reaches the inside of our eye – and in turn the quality of our vision.
If left untreated, cataracts lead to sight loss and eventual blindness. A staggering number of people lose their site to cataracts – there are 17 million worldwide, with 28,000 new cases reported every day.
Cataracts most commonly affect older people. In the US, for example, around 25 per cent of over 65s’ encounter a significant loss of vision due to cataracts. And this rises to 50 per cent for people over the age of 80.
Surgery is often sought as a solution, and cataract removal is widely recognised as one of the safest operations in the world today.
But the operation does carry risks. In the US, around 30 to 50 per cent of patients undergoing cataract removal require further laser treatment within two years. And of the 1.35 million people in the States who have the operation every year, around 2 per cent (approximately 27,000 people) develop serious complications following cataract surgery.
As we’ve discovered, tissue-damaging free radicals are a key factor behind the development of cataracts. This is compounded by a process known as glycation, where our tissues react with the glucose in our bodies to alter and stiffen over time. Together, free radicals and glycation create a ‘double whammy’ effect. They allow the proteins in our eyes to bind together, developing a film that blocks light and impairs vision.
Can-C’s powerful N-acetylcarnosine (NAC) compound has been proven to reduce both free radical and glycation development – one of the reasons it has been heralded as a breakthrough in the treatment of cataracts and other degenerative eye conditions.
Extensive research by Can-C pioneer Dr Mark Babizhayev, respected for his work at the Helmoltz Research Institute for Eye Diseases in Moscow, began in 1991.
Landmark research on a group of Russian patients, with an average age of 65 and suffering from age-related cataract, cantered on the use of NAC eye drops with a one per cent concentration. The patients applied the drops into their eyes twice daily, for a period of six months.
The study found:
And the patients reported few side effects.
Commenting on the research, Dr Babizhayev said: “For most patients treated, drug tolerance was good and no side effects were specifically associated with the application of 1 per cent NAC. What is more, no recurrence of cataract development occurred during the period of NAC application.”
Further studies have demonstrated the wider benefits of Can-C eye drops. A Russian study of patients aged 48 to 60, with no cataract problems but varying degrees of eye impairment – revealed significant benefits through use of the NAC drops. Eye tiredness was eliminated and vision boosted, while the subjects reported the treatment ‘brightened’ and ‘relaxed’ their eyes.
And although information has yet to be published on other conditions, Can-C’s N-acetylcarnosine formula could also help with a variety of eye conditions including:
The Can-C NAC formula has been painstakingly perfected by Dr Babizhayev and the team at Innovative Vision Products. Many other forms of carsonine were tested and rejected during their extensive research.
Can-C’s significance is highlighted in the book ‘The Cataract Cure” – in which one of Britain’s most prominent anti-ageing physicians, Marios Kyriazis, explores the remarkable story of NAC.
The book states: “Commercially available eye drops used against cataract – such as Can-C for example – contain special formulations of N-acetylcarosine and other ingredients.”
He continues: “The makers of Can-C eye drops are a company called Innovative Vision Products (IVP). They are the holders of worldwide patents for the use of NAC eye drops, manufactured to match the exact combination of ingredients used in the clinical research experiments.”
Can-C is the genuine formula. Synthesised, high-purity NAC – that’s tried, tested and proven to help in the treatment of cataracts.
This latest anti-aging breakthrough is a special form of Carnosine, called N-acetylcarnosine, a natural antioxidant, that has achieved remarkable results, because for the first time an eye-drop have been clinically proven to be successful in the condition of senile cataract.
Dr. Babizhayev who headed the Russian research team (Innovative Vision Products) that developed this innovative treatment, has stated that the maximum obtainable results are usually achieved in a 3 to 5 month period, however there are often noticeable benefits within only 1-month.
Can-C eye-drops are sold as an eye-lubricant, but are being used in parts of the world to improve glare sensitivity, enhance color perception and slow and even reverse the effects of senile cataract.
Marios Kyriazis, M.D., has written a booklet on the subject entitled 'The Cataract Cure.' In it he states that the research highlights that quality and formula are essential to both efficacy and long-term safety.
To ensure that you are purchasing an officially approved and tested product, the packaging should clearly state that it is approved by IVP. We are pleased to inform you that Can-C is the world's first N-acetylcarnosine eye-drop to meet the strict criteria laid down by IVP and is therefore officially approved by IVP.